I. AMENDMENTS

IN THE SPECIFICATION:

At page 1, please delete the existing title and insert therefor the following:--ADENOVIRUS p53 COMPOSITIONS AND METHODS--.

At page 2, please delete lines 3-7 and insert therefor the following: 1--This is a continuation of co-pending application Serial No. 07/960,513 filed October 13, 1992, which is a CIP of 07/665,538 filed March 6, 1991. The government owns rights in the present invention pursuant to NIH grants RO1 CA 45187 and CA 16672--.

IN THE CLAIMS:

Please cancel claims 1-65 without prejudice or disclaimer.

Please add the following new claims:

- --66. An adenovirus vector compaising a wild type p53 gene under the control of a promoter.
- 67. The vector of claim 66, wherein the promoter is the CMV promoter.
- 68. The vector of claim 66, wherein the promoter is the β -actin promoter.
- 69. The vector of claim 66, wherein the promoter is the SV40 promoter.
- 70. The vector of claim 66, wherein the promoter is the RSV promoter.
- 71. The vector of claim 66, wherein the wild type p53 gene is a human gene.

- A method of treating a cancer cell in a patient comprising introducing to the cell an adenovirus vector comprising a wild type p53 gene under the control of a promoter.
- 73. The method of claim 72, wherein the promoter is the CMV promoter.
- 74. The method of claim 72, wherein the cancer cell is a lung cancer cell.
- 75. The method of claim 74, wherein the lung cancer cell is a NSCLC cell.
- 76. The method of claim 72, wherein the cancer cell is in a tumor.
- 77. The method of claim 76, wherein the tumor is an endobronchial tumor.
- 78. The method of claim \(\frac{1}{2} \) further comprising resecting the tumor.
- 79. The method of claim 78, wherein the tumor resection occurs prior to introduction of the vector.
- 80. The method of claim 79, wherein the vector is directly introduced into the residual tumor site.
- 81. The method of claim 72, wherein the vector is introduced to the cell by regional delivery to the patient.
- 82. The method of claim 72, wherein the vector is introduced to the cell by lavage to the patient.
- 83. A method for treating a cell having a mutant p53 gene comprising introducing to the cell an adenovirus vector comprising a wild type p53 gene under the control of a promoter.